Unwanted by AbbVie and Infinity, battered Verastem gets an OK for duvelisib and a second shot at success
Verastem $VSTM is getting its proverbial second chance.
Once battered, bruised and left on the ropes after the complete failure of the initial strategy mapped …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
